Two HDAC inhibitors have received US FDA approval for treating cutaneous T-cell lymphoma patients, and many other HDAC inhibitors are currently in clinical trials34, 35. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.